Travere Therapeutics Statistics
Share Statistics
Travere Therapeutics has 87.03M shares outstanding. The number of shares has increased by 1.79% in one year.
| Shares Outstanding | 87.03M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.48% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 85.74M |
| Failed to Deliver (FTD) Shares | 24.55K |
| FTD / Avg. Volume | 1.4% |
Short Selling Information
The latest short interest is 7.99M, so 9.18% of the outstanding shares have been sold short.
| Short Interest | 7.99M |
| Short % of Shares Out | 9.18% |
| Short % of Float | 9.32% |
| Short Ratio (days to cover) | 3.92 |
Valuation Ratios
The PE ratio is -5.99 and the forward PE ratio is -15.85.
| PE Ratio | -5.99 |
| Forward PE | -15.85 |
| PS Ratio | 4.6 |
| Forward PS | 4.3 |
| PB Ratio | 3.32 |
| P/FCF Ratio | -2.07 |
| PEG Ratio | n/a |
Enterprise Valuation
Travere Therapeutics Inc. has an Enterprise Value (EV) of 1.01B.
| EV / Earnings | -9.1 |
| EV / Sales | 6.98 |
| EV / EBITDA | -3.11 |
| EV / EBIT | -2.69 |
| EV / FCF | -3.15 |
Financial Position
The company has a current ratio of 3.47, with a Debt / Equity ratio of 1.9.
| Current Ratio | 3.47 |
| Quick Ratio | 3.41 |
| Debt / Equity | 1.9 |
| Total Debt / Capitalization | 65.55 |
| Cash Flow / Debt | -0.73 |
| Interest Coverage | -33.24 |
Financial Efficiency
Return on equity (ROE) is -0.55% and return on capital (ROIC) is -62.25%.
| Return on Equity (ROE) | -0.55% |
| Return on Assets (ROA) | -0.14% |
| Return on Capital (ROIC) | -62.25% |
| Revenue Per Employee | 382.21K |
| Profits Per Employee | -293.16K |
| Employee Count | 380 |
| Asset Turnover | 0.18 |
| Inventory Turnover | 1.22 |
Taxes
| Income Tax | 223.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 99.77% in the last 52 weeks. The beta is 0.7, so Travere Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.7 |
| 52-Week Price Change | 99.77% |
| 50-Day Moving Average | 17.93 |
| 200-Day Moving Average | 10.91 |
| Relative Strength Index (RSI) | 44.5 |
| Average Volume (20 Days) | 1.75M |
Income Statement
In the last 12 months, Travere Therapeutics had revenue of $145.24M and earned -$111.40M in profits. Earnings per share was $-1.5.
| Revenue | 145.24M |
| Gross Profit | 133.79M |
| Operating Income | -376.74M |
| Net Income | -111.40M |
| EBITDA | -326.25M |
| EBIT | -376.74M |
| Earnings Per Share (EPS) | -1.5 |
Balance Sheet
The company has $58.18M in cash and $404.78M in debt, giving a net cash position of -$346.61M.
| Cash & Cash Equivalents | 58.18M |
| Total Debt | 404.78M |
| Net Cash | -346.61M |
| Retained Earnings | -1.13B |
| Total Assets | 504.41M |
| Working Capital | 134.70M |
Cash Flow
In the last 12 months, operating cash flow was -$280.02M and capital expenditures -$668.00K, giving a free cash flow of -$322.28M.
| Operating Cash Flow | -280.02M |
| Capital Expenditures | -668.00K |
| Free Cash Flow | -322.28M |
| FCF Per Share | -4.34 |
Margins
Gross margin is 92.12%, with operating and profit margins of -259.4% and -76.7%.
| Gross Margin | 92.12% |
| Operating Margin | -259.4% |
| Pretax Margin | -258.96% |
| Profit Margin | -76.7% |
| EBITDA Margin | -224.63% |
| EBIT Margin | -259.4% |
| FCF Margin | -221.9% |
Dividends & Yields
TVTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -8.67% |
| FCF Yield | -21.4% |
Analyst Forecast
The average price target for TVTX is $22, which is 27.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $22 |
| Price Target Difference | 27.2% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
Stock Splits
The last stock split was on Nov 2, 2012. It was a backward split with a ratio of 1:9.
| Last Split Date | Nov 2, 2012 |
| Split Type | backward |
| Split Ratio | 1:9 |
Scores
| Altman Z-Score | -3.56 |
| Piotroski F-Score | 4 |